Multiple sclerosis

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 285-302

  Keegan, B Mark ^a   Noseworthy, John H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Genetics; Glatiramer acetate; Interferon beta; Pathogenesis; Pathology

Indexed keywords

BETA1A INTERFERON; CREATININE; GLATIRAMER; GLUTATHIONE TRANSFERASE; HLA DR2 ANTIGEN; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; MYELIN; PREDNISONE; THYROTROPIN; TUMOR NECROSIS FACTOR;

ANEMIA; AUTOIMMUNITY; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELLULAR IMMUNITY; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DEPRESSION; DISEASE COURSE; DRUG CONTRAINDICATION; DYSPNEA; ENVIRONMENTAL FACTOR; EOSINOPHILIA; FEVER; GENETIC SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; HYPOTENSION; IMMUNOPATHOGENESIS; INSOMNIA; IRRITABILITY; MULTIPLE SCLEROSIS; MYALGIA; MYELINATION; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ATROPHY; AUTOIMMUNE DISEASES; CEREBRAL CORTEX; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PEPTIDES; SPINAL CORD;

EID: 0036187060     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.103909     Document Type: Review

References (96)

1. Revised estimate of the prevalence of multiple sclerosis in the United States
2. Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota
3. Histologie de la sclérose en plaques
4. Progress in determining the causes and treatment of multiple sclerosis
5. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
6. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
7. Acute leukoencephalopathies: Differential diagnosis and investigation
8. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet's disease involving the nervous system
9. Practice parameter: The usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology
10. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
11. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis
12. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis
13. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
14. The open ring. A new imaging sign in demyelinating disease
15. Open-ring imaging sign: Highly specific for atypical brain demyelination
16. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
17. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
18. A longitudinal study of brain atrophy in relapsing multiple sclerosis
19. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression
20. Primary progressive multiple sclerosis
21. Defining the clinical course of multiple sclerosis: Results of an international survey
22. The natural history of multiple sclerosis: A geographically based study 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation
23. Relapses and progression of disability in multiple sclerosis
24. The natural history of multiple sclerosis
25. The natural history of multiple sclerosis: A geographically based study. III. Multivariate analysis of predictive factors and models of outcome
26. Risk factors for multiple sclerosis: Race or place?
27. The geography of multiple sclerosis reflects genetic susceptibility
28. Occurrence of multiple sclerosis in the north and south of New Zealand
29. Multiple sclerosis: Hopeful genes and immunology
30. Multiple sclerosis in Australia and New Zealand: Are the determinants genetic or environmental?
31. Multiple sclerosis: Genomic rewards
32. Evidence for genetic basis of multiple sclerosis
33. A genetic basis for familial aggregation in multiple sclerosis
34. A full genome search in multiple sclerosis
35. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22
36. A point mutation in PTPRC is associated with the development of multiple sclerosis
37. Glutathione S-transferase polymorphisms in multiple sclerosis: Their relationship to disability
38. APOE genotype is a major predictor of long-term progression of disability in MS
39. The clinical course of neuromyelitis optica (Devic's syndrome)
40. HLA-DP-associated susceptibility to the optico-spinal form of multiple sclerosis in the Japanese
41. Seeking genes for MS: Big risks for big gains
42. Viruses and multiple sclerosis
43. Absence of neurological deficits following extensive demyelination in a class 1-deficient murine model of multiple sclerosis
44. Molecular mimicry and autoimmunity
45. Ubiquitous pathogens - Links between infection and autoimmunity in MS?
46. Association between clinical disease activity and Epstein-Barr virus reactivation in MS
47. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis
48. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA
49. Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients
50. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis
51. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS
52. Two models of multiple sclerosis: Experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison
53. Adoptively transferred experimental autoimmune encephalomyelitis in SJL/J, PL/J, and (SJL/J × PL/J)F1 mice. Influence of I-A haplotype on encephalitogenic epitope of myelin basic protein
54. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis
55. Adhesion molecules in multiple sclerosis: A review
56. Multiple sclerosis: Fas signaling in oligodendrocyte cell death
57. The role of B cells and autoantibodies in multiple sclerosis
58. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: A comparative study
59. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation
60. Identification of autoantibodies associated with myelin damage in multiple sclerosis
61. Multiple sclerosis: Lessons from neuropathology
62. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
63. Axonal damage in acute multiple sclerosis lesions
64. Axonal transection in the lesions of multiple sclerosis
65. Magnetic resonance spectroscopy: Imaging axonal damage in MS
66. Magnetization transfer imaging in multiple sclerosis
67. Multiple sclerosis: Remyelination of nascent lesions
68. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis
69. Multiple sclerosis: Symptomatic therapies
70. Clinical viral infections and multiple sclerosis
71. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group
72. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
73. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
74. Mechanisms of action of glatiramer acetate in multiple sclerosis
75. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
76. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
77. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
78. Randomized double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis
79. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis
80. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 multiple sclerosis study group
81. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
82. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
83. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
84. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
85. Mitoxantrone in progressive multiple sclerosis: MRI results of the European phase III trial
86. An open-trial evaluation of mitoxantrone in the treatment of progressive MS
87. Clinical safety and tolerance of mitoxantrone
88. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
89. Effect of interferon β-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial
90. Interferon beta 1-b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial
91. TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study
92. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
93. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
94. Immunoglobulins promote remyelination in the central nervous system
95. IVIg does not reverse established weakness in MS: A double-blind, placebo-controlled trial